Rezolute opened lower at $4.06, compared with its previous close of $4.07. In the last trading session, the stock traded between $3.85 and $4.13. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Rezolute is now worth
$ 62.28
Resulting in a loss of
$ 37.72 (37.72%)
Note: Past profits do not guarantee future returns.
Rating from 8 Analysts
Today's Change
$-0.20 (-4.82%)
Day High
$4.13
Day Low
$3.85
Day Open
$4.06
Prev Close
$4.07
Volume
8,82,756
1W Return
-2.05%
1M Return
-20.65%
3M Return
-16.06%
6M Return
22.21%
1Y Return
-61.41%
Market Cap ($ Mn)
375
PE Ratio
-
PB Ratio
3.82
PEG Ratio
-
ROE
-64.29%
ROCE
-67.97%
EPS (TTM)
$-0.19
1 Week
-2.05%
1 Month
-20.65%
3 Months
-16.06%
6 Months
22.21%
9 Months
14.96%
Rezolute files prospectus for $400 million mixed shelf offering
Rezolute Inc filed a prospectus for a $400 million mixed shelf offering. The registration covers various securities types under a single umbrella. Filing enables flexible future capital raises based on market conditions.
7 days agoRezolute completes enrollment in Phase 3 study of ersodetug
Rezolute completes enrollment in Phase 3 upLIFT study for tumor hyperinsulinism. Topline data for ersodetug expected in mid-December 2026. Interim results show 7 of 8 early participants met primary endpoint criteria.
29 days agoFDA recommends pre-BLA meeting for Rezolute's congenital HI drug
FDA recommends pre-BLA meeting for ersodetug despite missed primary endpoints in sunRIZE trial. Agency cited limitations of SMBG measures, requesting independent CGM data review. Open-label extension shows sustained glycemic control and reduced standard-of-care reliance over two years. Shares traded lower by 1.37% at $3.96 after initial gains.
1mo agoRezolute Q4FY26 Results: EPS misses estimate at $(0.20), net loss narrows
Net loss narrowed to $20.5 million in Q4FY26 from $24.4 million in Q4FY25. EPS of $(0.20) missed analyst consensus of $(0.15) by 33.33%. Cash and investments declined to $107.8 million from $167.9 million. R&D expenses fell to $53.8 million while G&A rose to $29.2 million.
1mo agoRezolute to participate in three major healthcare investor conferences
Rezolute management to speak at Cantor, H.C. Wainwright, and Morgan Stanley conferences. Events scheduled for September 9-16, 2026. Participation includes fireside chats and one-on-one investor meetings. Company focuses on treating refractory hypoglycemia due to hyperinsulinism.
2mo agoRezolute highlights ENDO data on congenital HI outcomes and tumor HI case series
Rezolute, Inc. presented four data analyses at the Endocrine Society meeting, focusing on congenital hyperinsulinism (HI) natural history and the efficacy of ersodetug. A case series from the Expanded Access Program showed 75% of tumor HI patients discontinued IV dextrose/TPN. The presentations support the therapeutic benefit of ersodetug in treating refractory hypoglycemia.
4mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 5 years ago in Rezolute is now worth
$ 62.28
Resulting in a loss of
$ 37.72 (37.72%)
Note: Past profits do not guarantee future returns.
